Infective Endocarditis — Written Clinical Reasoning

SAQ 1 — Integrated Management (25 marks, 35 minutes)

Prompt: Outline your integrated management plan for this patient, including the problem list, Modified Duke criteria classification, immediate investigations, antibiotic regimen, surgical decision, anticoagulation management, and complication surveillance. Justify each decision with reference to evidence and guidelines. ^[1]

Model Answer

Problem list (3 marks):

1. Prosthetic valve infective endocarditis (mechanical mitral valve) due to methicillin-sensitive Staphylococcus aureus — definite by Duke criteria
2. New paravalvular regurgitation with pulmonary oedema — heart failure, potential surgical indication
3. Transient ischaemic attack / embolic event 3 days ago — neurological complication
4. Acute kidney injury (creatinine 145, baseline 90) — multifactorial
5. Atrial fibrillation (rate 96) — likely chronic given mechanical valve
6. Anticoagulation management — warfarin for mechanical valve in the setting of IE and recent embolic event ^[1]

Modified Duke classification (2 marks): This patient has definite IE:

• Major 1: typical organism (Staphylococcus aureus) in blood cultures from three separate sites
• Major 2: echo evidence of endocardial involvement (vegetation on prosthetic mitral valve with new paravalvular regurgitation)
• Minor: predisposition (prosthetic valve), fever, vascular phenomena (Janeway lesions — painless palmar macules), immunological phenomena (Osler node — painful finger pad nodule) ^[1]

Two major criteria establish definite IE. Note that S. aureus bacteraemia is itself a Duke major criterion regardless of nosocomial acquisition or removable source. ^[1]

Immediate investigations (3 marks):

1. Transoesophageal echocardiography (TOE) — mandatory in all prosthetic valve IE and in any case with suspected paravalvular complication. TTE has low sensitivity for PVE. TOE will define the vegetation, assess for paravalvular abscess, dehiscence, fistula, and evaluate the severity and mechanism of regurgitation.
2. ECG monitoring — continuous telemetry to detect new conduction block (PR prolongation, bundle branch block, complete heart block), which would indicate paravalvular abscess extension into the conducting system.
3. CT head — to characterise the neurological event (TIA vs completed infarct vs haemorrhage), which critically influences the timing of any surgery. CT angiography of cerebral vessels if mycotic aneurysm suspected.
4. Repeat blood cultures — to document clearance and guide duration of therapy.
5. Dental review — to identify the portal of entry for oral streptococci (though this is Staphylococcus aureus, suggesting a different source — IV line, skin, healthcare exposure). ^[1]

Antibiotic regimen (4 marks): Empiric therapy was appropriate — MSSA covered by a bactericidal beta-lactam. For prosthetic-valve staphylococcal endocarditis: beta-lactam or glycopeptide backbone PLUS rifampin PLUS gentamicin synergy, at least 6 weeks from first effective therapy. Rifampin joins only after days of effective therapy once bacteraemia clears — never during high-inoculum bacteraemia. With AKI, aminoglycosides need cautious level-monitored use or omission.^[1]

Note the regional delta: ANZ Therapeutic Guidelines and ESC support this triple approach for staphylococcal PVE. Rifampin induces warfarin metabolism significantly — INR will fall and warfarin dose will need substantial upward adjustment, or conversion to heparin. ^[1]

Surgical decision (6 marks): This patient has multiple surgical indications and should be referred urgently to the Endocarditis Team and cardiac surgery:

1. Heart failure — the strongest indication. New paravalvular regurgitation causing pulmonary oedema, elevated JVP, and bibasal crackles. Heart failure from a surgically correctable valvular lesion mandates surgery — urgent for NYHA II–III with severe regurgitation, haemodynamic compromise, or large vegetations.
2. Prosthetic valve IE with Staphylococcus aureus — PVE with S. aureus has high medical-therapy failure rates; early surgery is generally favoured.
3. New paravalvular regurgitation — suggests possible paravalvular dehiscence, which is a mechanical complication requiring surgical correction.
4. Embolic event — the recent TIA indicates active embolisation, further supporting early surgery. ^[1]

The timing of surgery is modified by the neurological event. After a TIA, surgical risk is usually low and surgery proceeds without delay. With cerebral emboli or bleeding, indication and timing need specialist input (evidence gap, RCTs required). If heart failure is refractory and life-threatening, early surgery may proceed after neurosurgical consultation. ^[1]

The Kang RCT (37 early surgery vs 39 conventional; 3% vs 23% composite of death and embolism at 6 weeks, no mortality difference) supports early surgery for large vegetations — though it excluded stroke and PVE. ^[5]

Anticoagulation management (3 marks): This patient has a mechanical mitral valve requiring lifelong anticoagulation. In the setting of IE with a recent embolic event and planned surgery:

1. Stop warfarin and convert to unfractionated heparin infusion (short half-life, fully reversible) — this allows rapid reversal before surgery and rapid re-establishment after.
2. Monitor INR down to a safe pre-surgical level per local cardiac-surgery protocol.
3. Beware rifampin-warfarin interaction — potent enzyme induction markedly increases warfarin clearance, needing large dose increases. Heparin avoids this issue during the rifampin phase.
4. Do not switch to a DOAC — mechanical valves require warfarin; DOACs are contraindicated in mechanical valves. ^[1]

Complication surveillance (2 marks):

• Daily clinical assessment for heart failure, embolic events, new murmurs
• Serial ECG for conduction block (paravalvular abscess)
• Repeat TOE if clinical deterioration, persistent fever, new conduction block, or before surgery
• Renal function and electrolytes daily (AKI monitoring, especially if gentamicin used)
• Repeat blood cultures until clear, then periodically
• Temperature charting daily; persistent fever on appropriate therapy suggests uncontrolled infection or metastatic focus ^[1]

Communication and follow-up (2 marks):

• Endocarditis Team referral immediately (cardiology, infectious diseases, cardiac surgery, microbiology)
• Discuss surgical risk with patient and family — prosthetic-valve disease carries high surgical risk
• Counsel on prolonged IV antibiotic course (at least 6 weeks from first effective therapy), likely via PICC line and outpatient treatment
• Dental review to identify portal of entry
• Screen for healthcare-associated source (recent IV lines, procedures)
• Post-treatment: echocardiographic surveillance, lifelong prophylaxis (already high-risk), education on recurrence symptoms ^[1]